Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOLIPANC
2024-512951-18-00Phase 2Suspended
- Sponsor
- University of Cologne
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC), sponsored by University of Cologne. Primary endpoint: Overall survival after R0/R1 resection (OS-res). Started Sep 2024; status: suspended.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-512951-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512951-18-00.